EGFR and esophageal squamous cell carcinoma: Recently, biological agents that target epidermal growth factor receptor (e.g., gefitinib)42 and programmed cell death protein 1 (PD-1) pathway (e.g., nivolumab)43 have been tested for advanced ESCC patients who are refractory to multipronged therapy.